Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

The Associated Press reported today that German dialysis clinic operator Fresenius has been approved to purchase APP Pharmaceuticals. APP makes injectable drugs, including heparin, and just announced its plans to begin manufacturing heparin at its Puerto Rico facility after receiving approval by the U.S. Food & Drug Administration (FDA).

According to information on its web site, Fresenius, based in Hamburg, Germany, is the world’s largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure. It estimates more than 1.6 million people are affected by kidney failure worldwide.

The AP says the purchase of APP Pharmaceuticals will help Fresenius lower its expenses. Heparin is used by patients on kidney dialysis.

U.S. regulators approved the purchase, which is expected to close by mid-September, according to the AP report. As a result of the sale, APP Pharmaceutical shares rose 13 cents to $23.80, the AP reports.

This entry was posted on Wednesday, September 3rd, 2008 at 4:50 pm and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.